Abstract :
nfliximab is a chimeric monoclonal antibody that blocks TNF-α. Infliximab has been gained FDA approval in 1998 against autoimmune diseases such as Crohn’s disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriasis, psoriatic arthritis, and Behcet’s disease (1).
In recent, we are lives in the pandemic era with coronavirus disease 2019 (COVID-19). There are more than 35.1 million cases who are infected with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and 1.04 million deaths. Unfortunately, there is no specific antiviral therapy against COVID-19 (2). According to the literature, a small part of SARS-Co-2 infected cases were developed to acute respiratory distress syndrome (ARDS) and multi-organ failure. It has been suggested that intensive inflammatory response, cytokine storm syndrome, plays a central role in constitutive inflammatory cytokine production and susceptibility to acute ARDS. Therefore, in the current situation that there are no antiviral FDA-approved drugs, immunotherapy is the only solution for the treatment of severe SARS-CoV-2-infected cases (3). It has been suggested that the Infliximab can prevent overexpression of pro-inflammatory cytokines i.e., TNF-α, IL-6, and C-reactive protein (CRP) by which prevents cytokines storm and disease severity such as ARDS (3, 4). In the present literature, we evaluated all available evidence for the efficacy of Infliximab against patients with COVID-19.
